Iprixon (Ipratropium Bromide, Salbutamol)

Iprixon, a bronchodilator combination, is indicated for conditions involving reversible airway obstruction.

• Asthma: provides rapid relief of bronchospasm and improves airflow during acute episodes.
• Chronic obstructive pulmonary disease (COPD): reduces bronchoconstriction and eases breathing in acute exacerbations.
• Exercise‑induced bronchospasm: delivers quick bronchodilation to prevent symptoms triggered by physical activity.

• Ipratropium bromide acts as a muscarinic receptor antagonist, blocking acetylcholine‑mediated bronchoconstriction, while salbutamol is a selective β2‑adrenergic agonist that stimulates cyclic AMP formation, leading to relaxation of airway smooth muscle. The combined effect produces additive bronchodilation, improving airway caliber and facilitating airflow in obstructive lung diseases. The antagonism reduces parasympathetic tone, and the β2‑stimulus increases intracellular cAMP, which inhibits calcium influx, further preventing muscle contraction.

Iprixon may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Cough or throat irritation: mild irritation of the upper airway after inhalation.
• Dry mouth: reduced salivary secretion leading to a dry sensation.
• Tremor: fine shaking of the hands, especially at higher doses.
• Headache: mild to moderate headache episodes.
• Palpitations: sensation of rapid or irregular heartbeat.
• Nausea: occasional feeling of stomach upset.

Serious or Rare Side Effects

• Paradoxical bronchospasm: worsening of breathing difficulty after use.
• Tachyarrhythmia: rapid heart rhythm that may require medical attention.
• Angina pectoris: chest pain due to reduced cardiac blood flow.
• Severe hypotension: marked drop in blood pressure.
• Anaphylactic reaction: life‑threatening allergic response with rash, swelling, and airway compromise.
• Hyperglycaemia: elevated blood glucose levels, particularly in diabetic patients.

Before prescribing Iprixon, clinicians should consider several precautionary measures to ensure safe use.

• Cardiac history: evaluate patients with arrhythmias or ischemic heart disease for possible tachycardia or angina.
• Thyroid disease: monitor hyperthyroid patients as β2‑agonists may exacerbate symptoms.
• Diabetes: observe blood glucose as salbutamol can raise glucose levels.
• Elderly patients: start with the lowest effective dose and watch for increased sensitivity to anticholinergic effects.
• Concomitant β‑blockers: avoid use with non‑selective β‑blockers as they may diminish bronchodilator response.
• Store at room temperature: keep the inhaler below 25 °C, protect from moisture and direct sunlight, and retain in the original packaging.

Iprixon can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Non‑selective β‑blockers: may antagonize salbutamol’s bronchodilatory effect and precipitate bronchospasm.
• MAO inhibitors or tricyclic antidepressants: can potentiate salbutamol‑induced cardiovascular effects.
• Anticholinergic drugs: combined use may increase anticholinergic burden leading to dry mouth, urinary retention, or glaucoma.

Moderate Interactions (Monitor Closely)

• Diuretics (e.g., thiazides): may enhance hypokalemia risk when combined with salbutamol.
• Theophylline: concurrent use may increase the likelihood of tachyarrhythmias.
• Monoamine oxidase inhibitors: may require dose adjustment of salbutamol.
• Other inhaled bronchodilators: overlapping therapy can increase side‑effect risk; monitor patient response.